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Abstract: Psoriasis is a chronic immune-mediated skin disease that involves the interaction of immune
and skin cells, and is characterized by cytokine-driven epidermal hyperplasia, deviant differentiation,
inflammation, and angiogenesis. Because the available treatments for psoriasis have significant
limitations, dietary products are potential natural sources of therapeutic molecules, which can repair
the molecular defects associated with psoriasis and could possibly be developed for its management.
Fisetin (3,7,30 ,40 -tetrahydroxyflavone), a phytochemical naturally found in pigmented fruits and
vegetables, has demonstrated proapoptotic and antioxidant effects in several malignancies. This study
utilized biochemical, cellular, pharmacological, and tissue engineering tools to characterize the effects
of fisetin on normal human epidermal keratinocytes (NHEKs), peripheral blood mononuclear cells
(PBMC), and CD4+ T lymphocytes in 2D and 3D psoriasis-like disease models. Fisetin treatment of
NHEKs dose- and time-dependently induced differentiation and inhibited interleukin-22-induced
proliferation, as well as activation of the PI3K/Akt/mTOR pathway. Fisetin treatment of TNF-α
stimulated NHEKs also significantly inhibited the activation of p38 and JNK, but had enhanced
effect on ERK1/2 (MAPK). In addition, fisetin treatment significantly decreased the secretion of
Th1/Th-17 pro-inflammatory cytokines, particularly IFN-γ and IL-17A by 12-O-tetradecanolylphorbol
13-acetate (TPA)-stimulated NHEKs and anti-CD3/CD28-activated human PBMCs. Furthermore,
we established the in vivo relevance of fisetin functions, using a 3D full-thickness human skin model
of psoriasis (FTRHSP) that closely mimics in vivo human psoriatic skin lesions. Herein, fisetin
significantly ameliorated psoriasis-like disease features, and decreased the production of IL-17 by
CD4+ T lymphocytes co-cultured with FTRHSP. Collectively, our data identify the prodifferentiative,
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antiproliferative, and anti-inflammatory effects of fisetin, via modulation of the PI3K-Akt-mTOR and
p38/JNK pathways and the production of cytokines in 2D and 3D human skin models of psoriasis.
These results suggest that fisetin has a great potential to be developed as an effective and inexpensive
agent for the treatment of psoriasis and other related inflammatory skin disorders.
Keywords: fisetin; psoriasis; normal human epidermal keratinocyte; cell signaling; cell differentiation;
proliferation; inflammatory cytokine; PBMC; CD4+ T lymphocyte; 3D psoriasis-like skin disease model

1. Introduction
The physical and immunological protective skin barrier function, mainly executed by the
outermost epidermis, is sustained through the tight regulation of epidermal keratinocyte proliferation
and differentiation, ultimately resulting in a dense, impenetrable stratum corneum [1]. In the normal
epidermis, keratins are the most abundant structural proteins that form the keratin intermediate
filament cytoskeleton [2]. Upon commitment to terminal differentiation, keratinocytes switch from
expressing proliferative keratin 5 and 14 (K5 and K14) in the basal epidermis to expressing the early
differentiation keratin 1 and 10 (K1 and K10) and associated induction of various differentiation-related
protein markers in the suprabasal epidermis, which upholds the skin barrier’s integrity. These markers
include keratin tonofilaments, the filament aggregating protein (filaggrin) [1,3,4], caspase-14 [5],
the enzyme transglutaminase [4], and loricrin, an impenetrable late cornified envelope protein.
Increased interactions between these proteins cause beneficial effects: enhancement of the skin’s natural
moisturizing factor and epidermal hydration; maintaining the stratum corneum barrier function and
skin integrity; and protecting the induction of inflammation by external stimuli. This cognate process
is dysregulated in several chronic inflammatory skin diseases including psoriasis and atopic dermatitis,
where lesioned skin keratinocytes exhibit hyperproliferation and aberrant differentiation, two crucial
disease hallmarks [6]. Moreover, the expression levels of several differentiation-related proteins
including caspase-14 [7], filaggrin [7], and loricrin [4,8] are downregulated in inflamed, porokeratotic,
psoriatic skin lesions compared to nonlesioned and normal skin. Skin keratinocytes serve as the
principal source of several pro-inflammatory mediators, including the cytokines interleukin (IL)-1, IL-6,
IL-8, IL-10, IL-12, IL-15, IL-18, and IL-20, tumor necrosis factor (TNF) [8,9], and the chemokines CXCL8,
CXCL11, and CCL20 [10]. In response to local stimuli, the production of these mediators can initiate
an inflammatory process in psoriasis. In addition to keratinocytes, immune cells play a predominant
role in chronic inflammatory skin diseases via the production of mediators such as IFN-γ, IL-17, IL-22,
IL-23, IL-36, and the chemokine IP-10 [11–17]. Keratinocytes also possess cytokine receptors that serve
as targets for activated T lymphocyte-derived IL-17 and IL-22, resulting in increased proliferation,
aberrant differentiation, and further cytokine production by keratinocytes [8].
Agents that possess direct antiproliferative, prodifferentiative, and anti-inflammatory effects in
epidermal keratinocytes and immune cells are potentially ideal candidates for treating inflammatory
skin disorders such as psoriasis. Efforts to develop treatments for psoriasis remain elusive, mostly
relying on small molecules and biologics [11–14]. Most of these treatments have significant limitations,
including high cost, the need for injections, adverse drug reactions, and a loss of efficacy over
time [15]. Thus, there is a need for the discovery and development of new, safe, and effective
mechanism-based therapeutics.
Dietary botanicals are important natural sources of biologically active products that possess the
inherent ability to rescind multiple disease features. Fisetin (3,7,30 ,40 -tetrahydroxyflavone) (Figure 1A
(inset)) is a bioactive flavonol abundantly found in many dietary botanicals, particularly in pigmented
fruits and vegetables, including apples, cucumbers, onions, persimmons, and strawberries [16–18].
Fisetin has been reported to possess pleiotropic effects in diverse disease models, including anticancer,
anti-inflammatory, and antioxidant activities [19–26].
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Recently, we and others, in the quest to define mechanism-based dietary antioxidants for disease
prevention, showed that at higher micromolar concentrations, fisetin treatment causes growth arrest,
apoptosis, and regression of both melanoma and UVB-induced cutaneous cancers by modulating
the activation of components of the PI3K/Akt/mTOR signaling pathway [21,23,27]. Furthermore,
we and others have recently shown that these pathways, which are frequently deregulated in diverse
cancers [28,29], are also overexpressed in psoriatic and atopic dermatitis skin lesions [30,31]. There is
limited knowledge regarding the role of fisetin in immune cells. In basophils, fisetin suppresses the
expression level of type-2 cytokines [32]. In mice, fisetin reduces the production of type-1 and type-2
cytokines by T lymphocytes [33] and attenuates NF-κB activity and IL17 production in an in vivo
allergic airway inflammation mouse model [34]. These observations led us to examine the potential
of fisetin as an agent to mitigate the three major hallmarks of psoriasis: activation of inflammation,
keratinocyte-induced proliferation, and aberrant differentiation [35]. To the best of our knowledge,
no study has evaluated the effects of fisetin on psoriasis. In this study, we assessed the effect of fisetin in a
psoriasis model, and demonstrated that at low (micromolar) concentrations fisetin inhibited intracellular
PI3K/Akt/mTOR and MAPK signaling components and normal human epidermal keratinocyte (NHEK)
proliferation, and promoted NHEK differentiation without inducing apoptosis. Moreover, fisetin
reduced the secretion of pro-inflammatory cytokines by keratinocytes; activated peripheral blood
mononuclear cells (PBMC) and CD4+ T lymphocytes; and mechanistically inhibited the intracellular
PI3K/Akt/mTOR and MAPK pathways. Furthermore, the functional characteristics/roles of fisetin were
also examined in an established in vivo relevant 3D full-thickness engineered human psoriasis-like skin
model. Our study demonstrates that fisetin acts on both inflamed keratinocytes and immune cells in
2D and reconstituted 3D skin tissue architecture, similar to in vivo psoriatic skin lesions, and clarifies
its mechanism of action in these systems.
2. Materials and Methods
2.1. Chemicals and Reagents
Fisetin, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide (MTT), propidium
iodide (PI), and 12-O-tetradecanoyl-phorbol-13-acetate (TPA) were purchased from Sigma Chemical
Co. (St Louis, MO, USA). The antibodies for caspases (-3, -8, and -9), PARP, Bak, Bax, Bad, Bcl-2,
PathScan® Multiplex (Phospho-p90RSK, Phospho-Akt, Phospho-p44/42 MAPK (Erk1/2), Phospho-S6
Ribosomal Protein, and Rab11) Western Detection Cocktail I; #5301, Phospho-p38 MAPK (Thr180 /Tyr182 )
(D3F9) XP® Rabbit mAb #4511, Phospho-Akt (Ser473 ) (D9E) XP® Rabbit mAb #4060, Phospho-mTOR
(Ser2448 ) (D9C2) XP® Rabbit mAb #5536, Phospho-mTOR (Ser2481 ) Antibody #2974, Phospho-SAPK/JNK
(Thr183 /Tyr185 ) (81E11) Rabbit mAb #4668, β-Actin (13E5) Rabbit mAb #4970, PI3 Kinase p110α (C73F8)
Rabbit mAb #4249, PI3 Kinase p85 (19H8) Rabbit mAb#4257, Phospho-Akt (Thr308 ) (D25E6) XP® Rabbit
mAb #13038, PhosphoPlus® p70 S6 Kinase (Thr389 , Thr421 /Ser424 ) Antibody Kit #9430, mTOR (7C10)
Rabbit mAb #2983, and Lamin B1 (D4Q4Z) Rabbit mAb #12586 were obtained from Cell Signaling
Technology (Danvers, MA, USA). Recombinant human (rh) IL-22, IL-17A, TNF-α, anti-CD3, anti-CD28,
and biotinylated polyclonal goat antihuman IL-17A were from R&D Systems (Minneapolis, MN,
USA). Antihuman IL-17A, IFN-γ (clone 2G1) was purchased from Endogen (Pierce/Thermo Scientific,
Rockford, IL, USA), IFN-γ (clone B133.5), IL-4 (clone 8D4-8) and IL-4 (clone MP-25D2) (Pharmingen,
Inc., La Jolla, CA, USA), p-JNK (clone G-7,sc-6254), p-p38 (clone D-8, sc-7973), filaggrin (clone
AKH1,sc-66192), p-p38(sc-7973), cytokeratin-1(sc-65999), cytokeratin-10 (sc-51581), Transglutaminase
1 (sc-25786), Fra-1(sc-605X), c-Fos(sc-52X), Fos B(sc-8013), c-Jun(sc-1694), Jun B(sc-46x), Jun D(sc-74),
caspase-14 (sc-5628), were all obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
CELLnTEC progenitor cell culture medium was from ZenBio (ZenBio, Raleigh, NC, USA). Fetal bovine
serum (FBS) was obtained from Life Technologies (Grand Island, NY, USA). The transglutaminase
activity assay kit (C, K571-100) was from BioVision, Inc. (Milpitas, CA, USA). The Procarta Plex Mix
& Match Human 6-Plex kit was from eBioScience/Affymatrix (EPX060-15073; Santa Clara, CA, USA).
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Horseradish peroxidase conjugated antimouse or antirabbit secondary antibody was obtained from
Amersham Life Science, Inc. (Arlington Heights, IL, USA), and the BCA protein assay kit was obtained
from Pierce (Rockford, IL, USA). Novex precast Tris-glycine gels were obtained from Invitrogen
(Carlsbad, CA, USA).
2.2. Human Subjects
The study protocols were approved by the University of Wisconsin-Madison Health Sciences
Institutional Review Board protocols #2013-0059-CR004 and 2013-1570, and informed written consent
was obtained from subjects prior to participation. The study was conducted according to the principles
of the Declaration of Helsinki.
2.3. Keratinocyte Isolation, Culture, Activation with IL-22, TNF-α, TPA, and Treatments
Primary normal human epidermal keratinocytes were isolated from neonatal foreskin and adult
skin biopsies, and primary cultures were established in CELLnTEC progenitor cell culture medium
(ZenBio, Raleigh, NC, USA) supplemented with penicillin (100 U/mL), 100 µg/mL streptomycin
(100 µg/mL), and amphotericin (100 µg/mL) (Life Technologies), as previously described [36,37]. Frozen
cells were thawed and maintained for about two months (~8 passages). Human epidermoid carcinoma
A431 cells, obtained from ATCC (Manassas, VA, USA), and human immortalized keratinocytes HaCaT
cells from Life Technologies Corporation (ThermoFisher Scientific, Waltham, MA, USA) were cultured
and maintained in DMEM, supplemented with 10% FBS and 1% penicillin–streptomycin. Stock
solutions of fisetin were made in dimethyl sulfoxide (DMSO), and further diluted in the respective
growth media for the treatment of NHEK, A431, and HaCaT cells. Control cells were treated with
an equivalent volume of the vehicle alone, corresponding to a final maximum concentration of 0.1%
(v/v) DMSO for each treatment, at which point the concentration had no effect on the cell viability.
All cells were maintained at 37 ◦ C in a humidified atmosphere of 95% air and 5% CO2 , and the
growth media were replenished every alternate day until reaching desired confluence (60–80%) prior
to experimentation. For rhIL-22 stimulation and drug treatment protocol, near-confluent keratinocytes
were pretreated with or in the absence of varied concentrations of fisetin (10–20 µM) for 8 h, followed
by co-treatment with or without rhIL-22 (20 ng/mL) for 40 h (making a total of 48 h exposure to fisetin).
Cells were harvested and lysates were prepared for immunoblot as described below. IL-22-induced
cell proliferation and viability analysis in the presence or absence of fisetin were as described below.
For TNF-α treatment, cells were cultured and pretreated with fisetin overnight and were stimulated
with or without rhTNF-α (10 ng/mL) for 10 to 60 min prior to harvesting for Western blotting analysis,
as described below. For 12-O-tetradecanoyl-phorbol-13-acetate (TPA) stimulation, near-confluent
keratinocytes were pretreated with or without altered concentrations of fisetin (10–20 µM) for 20 h,
followed by co-treatment with or without 100 nM/mL of TPA for the final 6 h (for a total of 26 h of
exposure to fisetin). Cultured supernatants were centrifuged and centrifugates were collected and
stored at −80 ◦ C until used. The supernatants were only subjected to a single freeze-thaw cycle and
used for the analysis of TPA-induced keratinocytes secreted pro-inflammatory mediators (IL-1α, IL-1β,
IL-6, IL-8 (CXCL8), TGF-α and TNF-α according to the manufacturer’s protocol and as previously
described [38], and as described below.
2.4. Determination of Cell Viability by MTT Assay
The
effect
of
fisetin
on
the
viability
of
cells
was
determined
by
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide (MTT) assay. NHEK, A431 and
HaCaT cells were plated at 5 × 103 cells per well in 200 µL of respective culture media in 96-well
microtiter plates. After the cells were adherent and proliferating, the media containing fisetin
(0–80 µM) were replenished and cultured for 24 or 48 h. After incubating for the specified times, MTT
solution (0.5 mg/mL in phosphate-buffered saline (PBS)) was added to each well and incubated for 3 h,
after which the plate was centrifuged at 2000 rpm for 5 min at 4 ◦ C.
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Additionally, the effect of fisetin treatment on the viability of NHEK was assessed in relation
to the proliferative effect following prestimulation with or without rhIL-22 (20 ng/mL) and was
determined by MTT assay. Briefly, NHEKs were seeded at a density of 2 × 104 cells/well in 24-well
poly(D)lysine (0.1 mg/mL; Sigma-Aldrich, St. Louis, MO, USA) precoated plates in 1 mL complete
culture medium and incubated at 37 ◦ C and 5% CO2 . At 80% confluence, cells were treated for 6 h
with/without fisetin 10–20 µM, after which rhIL-22 (20 ng/mL) was added and further cultured. At 48 h
of incubation, the medium was removed and cells were rinsed with PBS and incubated for 3 h with
150 µL of MTT solution (0.5 mg/mL in medium). In either case, the MTT solution was removed
and the formazan crystals were then solubilized in DMSO (200 µL) by shaking, and absorbance was
spectrophotometrically recorded at 570 nm on a Bio-Tek microplate reader (Bio-TEK Instruments Inc.,
Winooski, VT, USA). The experiment was repeated three times each sample performed in sextuplicate
with similar results. The effect of fisetin on normal and IL-22 stimulated growth inhibition was assessed
as percentage cell viability, where DMSO-treated cells (untreated controls) were considered 100%
viable. DMSO at the concentrations used has no effect on cell viability.
2.5. Cell Cycle Analysis
NHEKs were treated with fisetin (1-120 µM) for 24 h, harvested, and fixed in chilled 70% alcohol
overnight. Cells were then washed twice with PBS, digested with DNase-free RNase (10 µg/mL) at
37 ◦ C for 1 h, stained with PI (5 µg/mL) for 3 h at 4 ◦ C in the dark, and analyzed by FACS Calibur
(Becton Dickinson, Franklin Lakes, NJ, USA) for cell cycle phase distribution.
2.6. Preparation, Culture, Activation, and Treatment of Peripheral Blood Mononuclear Cells (PBMC)
Peripheral blood was obtained by venipuncture from volunteer healthy donors with appropriate
University of Wisconsin-Madison Health Sciences Institutional Review Board approval, as previously
described, with some modifications [39]. Briefly, heparinized whole blood was centrifuged (700× g,
20 min) over a Percoll density gradient (density 1.090 g/mL; Pharmacia Biotech, Piscataway, NJ, USA)
to separate mononuclear cells from granulocytes. PBMCs were then washed, layered over new calf
serum, and centrifuged at 800 rpm for 15 min to eliminate platelets. PBMCs were cultured in 24-well
dishes at 1.0 × 106 cells/mL with RPMI 1640, 10% FBS, and antibiotics. PBMCs were treated with fisetin
(10 µM) for 10 min, and then activated with anti-CD3 (R&D Systems; coated on plates at 1 µg/mL) plus
soluble anti-CD28 (R&D systems; 1 µg/mL). After 6 h of culture, RLT buffer (Qiagen, Valencia, CA,
USA) was added on cells for RNA extraction and PCR analysis. After 48 h of culture, cells’ supernatant
fluids were harvested for the measurement of proteins by ELISA.
2.7. Preparation and Activation of Blood CD4+ T Lymphocytes
The CD4+ T lymphocytes were prepared as previously described [40]. Briefly, heparinized blood
was diluted 1:1 in HBSS, and overlaid on Percoll (1.090 g/mL). After centrifugation at 700× g for
20 min at room temperature, the mononuclear cells were recovered from the plasma/Percoll interface,
and CD4+ cells were prepared by negative selection using the Miltenyi Biotec (San Diego, CA, USA)
CD4+ T Cell Isolation Kit II. Using this method, purity was typically >98% as determined by flow
cytometry [40]. For activation, CD4+ T cells (2 × 106 /mL) were cultured in 1 mL of complete medium
(RPMI plus 10% FBS) with 1 µg/mL of plate-bound anti-CD3 plus 1 µg/mL of soluble anti-CD28 (clones
37407 and UCHT1, respectively; R&D Systems, Minneapolis, MN, USA) in a 24-well plate (Corning
Costar, Lowell, MA, USA). In this condition, after 48 h activation, CD4+ T cells had a memory/effector
phenotype (CD45RO+ CD25+) as previously shown [40] and were placed with the tissue-engineered
reconstructions over it. CD4+ T cell subset purification was performed by positive selection with
magnetic bead separation (Miltenyi), and cell and FTRHSP-free supernatants’ cytokine levels were
detected by ELISA, as above.
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2.8. ProcartaPlexTM Multiplex Bead-Based Immunoassays for Cytokines and Chemokines
Cultured conditioned supernatant from TPA-stimulated and control keratinocyte cultures in the
presence or absence of varied concentration of fisetin were used to determine the levels of produced
cytokine and chemokine levels by human 6-Plex Procarta Multiplex Beads. A commercially available
human Procarta 6-Plex Bead immunoassay kit (Affymetrix/eBioscience) was used to determine cytokine
and chemokine levels in conditioned media from TPA-stimulated NHEKs as described earlier [38].
The assay includes a range of six customized human pro-inflammatory cytokine and chemokine panels
that reflect key processes and responses relating to the activation of keratinocyte inflammation. Beads
of defined spectral properties conjugated to analyte-specific capture antibodies were combined with
50 µL of cultured supernatant samples to be tested in separate wells of a 96-well black side/transparent
bottom microplate and incubated at room temperature (RT) for 120 min following the manufacturer’s
instructions and as previously described [38]. All cell culture supernatant samples were analyzed
in triplicate along with serial standards (7-point dilutions). After each analyte was allowed to bind
to the captured antibodies on the beads, washes were performed to remove nonspecifically bound
proteins, and analyte-specific biotinylated detection antibodies were added and incubated with the
beads at RT for 30–60 min. During this incubation, the analyte-specific biotinylated detection antibodies
bind to specific epitopes on the immobilized analytes. Following the binding incubation and washes,
streptavidin conjugated to phycoerythrin (SA-PE or streptavidin-PE), a pigment complex that serves as
a fluorescent tag, was added, and samples were incubated at RT with slow shaking for 30 min. During
this final incubation, streptavidin-RPE binds to the biotinylated detector antibodies associated with the
immune complexes on the beads, forming a four-member solid phase sandwich. After washing cycles
to remove unbound SA-PE, excess reading buffer was added and incubated at RT for a minimum of
5 min in the dark with shaking and stored at 4 ◦ C overnight. Fluorescently tagged beads were analyzed
with the xMAP Luminex reader (Luminex, Austin, TX, USA) for quantitative analysis. The spectral
properties of the beads and the amounts of associated PE fluorescence were monitored to determine
the concentration of the analytes IL-1α, IL-1β, IL-6, CXCL8 (IL-8), TNFα, and TGF-α in cultured
supernatants from different NHEK treatment groups. The analyte concentrations were determined by
importing the data into Procarta PlexTM Multiplex Analyst software v.1.0 (Affymetrix/eBioscience) for
analysis, as described earlier [38]. The cytokine/chemokine values obtained by immunoassay were
referenced against established standards to allow for comparisons between the study groups.
2.9. ELISA Analysis of Th1-Th2-and-Th17 Cytokines, IL-4, IL-17A, and IFN-γ
Supernatant cultures from antiCD3/antiCD28-stimulated PBMC in the presence or absence of
varied concentrations of fisetin were used to determine the levels of produced pro-inflammatory
cytokine levels by a sandwich ELISA immunoassay. Cytokines were measured in the 48 h PBMC
and CD4+ T cells’ supernatant fluids. IL-17 A, IFN-γ, and IL-4 levels were measured by utilizing
an “in-house” sandwich ELISA [40,41]. Coating antibodies included antihuman IL-17A (clone
41809.111, R&D Systems), IFN-γ (clone 2G1, Endogen/Pierce/Thermo Scientific), and IL-4 (clone 8D4-8,
Pharmingen, Inc.). Detection antibodies included biotinylated polyclonal goat antihuman IL-17A
(R&D Systems), IFN-γ (clone B133.5, Pharmingen, Inc), and IL-4 (clone MP-25D2, Pharmingen, Inc).
The ELISA assay sensitivities were < 5 pg/mL for others and < 3 pg/mL for IL-17A.
2.10. RNA Preparation and Real-Time Quantitative (q)-PCR
Total RNA was extracted from PBMC using the RNeasy Mini Kit (Qiagen). The reverse
transcription reaction was performed using the Superscript III system (Invitrogen/Life Technologies,
Grand Island, NY, USA). Gene expression levels were determined by qPCR using SYBR Green Master
Mix (SA Biosciences, Frederick, MD, USA). Forward and reverse specific primers ((IFNG), forward:
gaaacgagatgacttcgaaaagct, reverse: catgtattgctttgcgttgga, and (IL17A), forward: cgatccacctcaccttgga,
reverse: tcccagatcacagagggatatctctc) were designed using Primer Express 3.0 (Applied Biosystems,
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Carlsbad, CA, USA) to span an exon-exon junction, and blasted against the human genome to
determine the specificity using the National Center for Biotechnology Information - NCBI primer
blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast). The reference gene primers, β-glucuronidase
((GUSB), forward: caggacctgcgcacaagag, reverse: agcgtgtcgacccattc), were used to normalize the
samples. Standard curves and efficiencies were determined for each set of primers. Efficiencies
ranged between 91% and 96%. Data are expressed as a fold change using the comparative cycle
threshold (∆∆CT) method, as described previously [40]. The values presented are fold change =
(2−∆∆Ct ) compared to expression in resting PBMC.
2.11. Preparation of Protein Lysates from Cultured Cells and Western Blotting
Following the treatment of NHEK cells with fisetin (10–20 µM; for a maximum of 48 h prior
to harvest), in the presence or absence of TNF-α or rhIL-22, the media was aspirated, and the
cells were washed with cold PBS (pH 7.4). Cells were incubated in ice-cold lysis buffer (50 mM
Tris-HCl, 150 mM NaCl, 1 mM ethyleneglycol-bis(aminoethylether)-tetraacetic acid (EGTA), 1 mM
EDTA, 20 mM NaF, 100 mM Na3VO4, 0.5% NP-40, 1% Triton X-100, 1 mM phenylmethylsulfonyl
fluoride (PMSF) (pH 7.4), with freshly added protease inhibitor cocktail (Protease Inhibitor Cocktail
Set III, Calbiochem, La Jolla, CA, USA) on ice for 30 min. The cells were scraped and cell lysates collected
in microfuge tubes and passed through 22.5-gauge syringe needles to break up the cell aggregates.
The lysates were cleared by centrifugation at 14,000 g for 30 min at 4 ◦ C, and the supernatant (whole cell
lysate) protein concentrations were determined using a BCA protein assay kit (Pierce) according to the
manufacturer’s protocol. Lysates were used or immediately aliquoted and stored at −80 ◦ C for further
analysis. Western blotting was performed as previously described [30,42]. Briefly, 10-20 µg protein was
resolved on 4–12% polyacrylamide gels and transferred to a nitrocellulose membrane. The blots were
blocked in blocking buffer (5% nonfat dry milk or BSA/1% Tween 20; in 20 mM TBS, pH 7.6) for 45 min
at room temperature. Membranes were incubated with an appropriate monoclonal or polyclonal
primary antibody in the blocking buffer for 2 h at RT, to overnight at 4 ◦ C, followed by 3 × 5-min washes,
and incubated with antimouse or antirabbit horseradish peroxidase-conjugated (HRP) secondary
antibody obtained from Amersham Life Science Inc. Chemiluminescence and autoradiography
was detected using Bio-Rad detection and analysis systems, as described earlier [30,42]. Equal
loading of protein was confirmed by stripping the immunoblot and re-probing for β-actin, vinculin or
lamin B1 as loading controls. The immunoblot results displayed herein are representative of three
independent experiments.
2.12. Generation of a Three-Dimensional (3D) Full-Thickness Reconstituted Human Skin Model of
Psoriasis (FTRHSP)
A metabolically active 3D full-thickness reconstructed human skin model of psoriasis (FTRHSP)
was generated as described previously [36,37], with slight modifications. The FTRHSP consisted of a
multilayered NHEK in a highly differentiated epidermis developed on a fibroblast- contracted collagen
dermal substratum, and a suspension of activated CD4+ T cells underneath the 3D reconstructed
epithelium exposed at the air-liquid interface (ALI) for 12-14 days as described previously [36,37],
with slight modifications. The dermal component was prepared by contracting collagen gels populated
with fibroblasts seeded into 3.0 µm Millicell-PCF inserts (Millipore Corporation, Billerica, MA, USA),
each placed in wells of a 24-well plate as described previously, and the epidermal component was
generated on top [37,43]. For epidermal components, second- to third-passage NHEKs established
in low-calcium Epi-Life medium were seeded, synchronized, and maintained in progenitor cell
targeted culture media (CnT-02-07; CELLnTEC, ZenBio, Research Triangle Park, NC, USA) prior to
harvesting and used to generate the 3D FTRHSP cultures as described earlier [37,43]. Briefly, after
trypsinization, 3 × 105 cells per insert in 250 µL of CnT-02-07 were seeded into the surface of the
generated dermal substratum, each placed in wells of six-well tissue culture plates containing 2.5 mL
of CnT-02-07 medium in a humidified atmosphere with 5% CO2 and maintained at 37 ◦ C. After 48 h
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of culture, CnT-02-07 was switched to CnT-02-3DP5 differentiation medium (2 mL outside the insert,
and 0.4 mL inside the inserts (day 2)), and further grown for 48–72 h to initiate differentiation (day 5).
The media outside and inside the inserts were then removed, and the medium outside the insert was
replenished with 1.2 mL of CnT-02-3DP5 complete medium and cultured at ALI from this time point
onwards. After fivedays of cultures at ALI, the medium outside was replenished with prewarmed
CnT-02-3DP5 medium in plates containing coated anti-CD3 and soluble anti-CD28 stimulated CD4+ T
cells (3 × 105 /0.9 mL) (herein referred to as activated T cells), prepared as above (day 10) to initiate
inflammation. Anti-CD3/CD28 CD4+ T cells in 0.9 mL of medium in the transwells at day 10 were
overlaid by placing the insert on top, exposing the underneath dermal side of the 3D skin equivalents
on it. Memory T cells were activated, while control or inactivated CD4+ T cells were employed in
the control reconstructs. On the same day of co-culture of 3D and activated T cells, topical treatment
with or without different concentrations of the test compounds (fisetin or Vit-D3 ) was initiated. Fresh
media were replenished as above every other day and continued prior to harvest at the indicated
harvest day (day 15). After five days of co-culture in the presence or absence of the test compounds,
and at harvesting, 3-4 mm diameter punch biopsies from each insert were obtained, formalin-fixed,
and processed for either H&E or immunostaining. We then analyzed the morphology and protein
expression levels of markers of inflammation, proliferation, and differentiation as well as activation of
the PI3K/Akt/mTOR cascade. Additionally, cell-free supernatants were collected for pro-inflammatory
cytokine analysis using sandwich ELISA as described above.
2.13. Fisetin and Vit-D3 Treatment of the 3D FTRHSP Model System
Fisetin and Vit-D3 were dissolved in DMSO and stored as 80 mM, and 0.1 mM aliquots, respectively,
at −20 ◦ C protected from light. At the time of use, test compounds, fisetin (1–80 µM), or vit-D3 (0.1 µM)
were diluted in a culture medium containing 0.1% BSA to stabilize the drugs, and treatment was started
at 80% confluence (for monolayer). For the 3D FTRHSP studies exposed to ALI, 10 µL of different
concentrations of the test agents, fisetin (10–40 µM) and vit-D3 (1 × 10−7 µM), which are known to
control psoriasis, were added to the developing tissue.
2.14. Histology, Morphometry, and Immunostaining Analyses of the FTRHSP
Formalin-fixed, paraffin-embedded (FFPE) 5-µM cross sections were de-paraffinized by incubation
in xylene (soaking twice for 10 min each), rehydrated with ethanol (twice in 100% ethanol for 10 min,
twice in 95% ethanol for 10 min and then in 70% ethanol for 10 min), and finally placed in distilled
water for 10 min. Antigen retrieval was performed by treatment with fresh sodium citrate buffer with
0.05% Tween 20 at pH 6.0, for 30 min at 100 ◦ C, and sections were stained with H&E and evaluated
for gross morphology, epidermal, and horny layer thickness and immunostained for the specified
markers as previously described [37,44,45]. Briefly, endogenous peroxidase was blocked with 3%
H2 O2 in methanol and incubated with a blocking solution containing 3% bovine serum albumin
(BSA)/3% normal goat serum (NGS)/0.4% Triton X-100 in PBS for 60 min at RT, followed by overnight
incubation at 4◦ C with monoclonal antibodies (mouse cytokeratin 10 (RKSE 60) (1:75, sc-23877),
mouse anti-Desmoglein-1 (1:75, Invitrogen #326000), rabbit anti-filaggrin (1:100; ab34584); rabbit
anti-involucrin (1:75; 2215)). After three washes, samples were incubated for 2 h with Texas Red@-X
Goat Anti-mouse (1:600; Invitrogen T6390) and Alexa fluor Goat Anti-rabbit, (1:600; Life Technology
A11008), followed by three washes of 10 min each, and were mounted in situ mounting media with
40 ,6-diamidino-2-phenylindole (DAPI) (#DUO82040, Sigma). Slides were visualized on an Olympus
IX71 system microscope (Olympus/HuntOptic & Imaging, Inc., Pittsburgh, PA, USA), and digital
images at 20× magnification were captured with a Olympus U-CMAD3 adaptor attached Olympus
DP71 camera (Olympus/HuntOptic & Imaging, Inc.) linked to a high-resolution computer screen
and connected to an Olympus U-RFL-T Mercury Burner. Images were processed using the Olympus
CellSens dimension imaging software v1.6. The thickness in terms of the area of the entire epidermis
and the stratum corneum were determined as described earlier [37].
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2.15. Statistical Analysis
Statistical analyses were carried out with GraphPad Prism version 7.1 (San Diego, CA, USA),
except for qPCR and ELISA, which were performed using the SigmaPlot 11.0 software package
(Systat Software, Inc., San Jose, CA, USA). All quantitative data are expressed as means ± SD or SEM,
and significant
were determined by the Student’s t-test or ANOVA with Bonferroni
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Tukey post hoc testing; p values < 0.05 were considered significant.
and significant differences were determined by the Student’s t-test or ANOVA with Bonferroni
and/or Tukey post hoc testing; p values < 0.05 were considered significant.
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from these plots are shown. (C) Effects of fisetin on the percentage of cells population in the different
phases of cell cycle, and indication of late apoptosis or necrosis (i.e., PI-positive) cells were only seen in
cells treated with higher fisetin concentration. (D) Levels or percentahes of cell cycle distribution in
fisetin-treated cells as assessed by flow cytometry analysis. Bar graphs represent mean ± SD of results
from three independent experiments performed in triplicate. Statistical significance was determined
using one-way ANOVA and Dunn’s multiple comparison test and significance was considered when
p < 0.05 (*), as compared with the control. (E) and (F) Effect of different concentrations of fisetin on the
expression of markers of apoptosis including caspase-3, -8, and -9, PARP (85 kDa and 116 kDa) and
Bcl-2 family of proteins (Bcl2, Bax, and Bak) on cells harvested after 48 h of treatment as analyzed by
Western blotting. Equal protein loading was confirmed using β-actin as loading control. (F) Numerical
data above the blots represent relative quantitative density values for the blots normalized with an
internal loading control. The Western blot data shown are representative immunoblots of two to three
independent experiments with similar results.

To examine whether the effect of fisetin on viable cell number is related to cell cycle arrest or
apoptosis, the proportion of cells containing diploid (sub-G1 ) levels of DNA was quantified using
propidium iodide (PI) staining and flow cytometric analysis. Treatment with 90 and 120 µM of fisetin
as a positive control for apoptosis [46] significantly increased the proportion of NHEK in the sub-G1
population (6.9% and 8.24%) compared to lower doses of fisetin (30–60 µM) that only expanded the
G1 and increased the S-phase compartments (0% and 0.22%), but did not induce any increases in
keratinocyte apoptosis (Figure 1C,D). Fisetin at 5–30 µM did not exhibit toxicity, but cell death was
evident at higher doses (Figure 1C,D). Western blotting revealed that, at concentrations less than
or equal to 20 µM, fisetin did not induce apoptosis at the time points investigated, as evidenced by
the absence of activation of caspases 3, 8, and 9 and/or changes in PARP, Bak, Bax, and Bcl2 protein
levels (Figure 1E,F). These observations led us to select doses of 0 to 20 µM over 24–48 h for further
mechanistic studies.
3.2. Fisetin Treatment Promotes Human Primary Epidermal Keratinocyte Differentiation and Upregulates the
Expression of AP-1 Transcription Factor Proteins
Since psoriasis is characterized by aberrant keratinocyte differentiation, a key requirement
for epidermal homeostasis [10], we examined whether the antiproliferative effect of fisetin on
NHEK paralleled differentiation. The ability of different concentrations of fisetin to induce terminal
differentiation was analyzed by monitoring transglutaminase (TGase) enzyme activity, a marker of
terminal keratinocyte differentiation. Significant dose-dependent induction of TGase activity was
observed in NHEK (Figure 2A,B (graph for linear regression used to plot TGase activity)). In addition,
the ability of fisetin to stimulate differentiation was examined by Western blot analysis of the expression
levels of early (K1 and K10), intermediate (caspase-14) and late (filaggrin and TGase-1) keratinocyte
differentiation markers [36,47,48]. Following 24–48 h exposure of near-confluent NHEK, fisetin doseand time-dependently increased the expression of these differentiation markers (Figure 2C), indicating
that fisetin induces terminal differentiation of keratinocytes at higher concentrations.
Activator protein-1 (AP-1), a dimeric protein complex comprised of members of the Jun and
Fos proto-oncogene subfamilies, is a transcription factor known to play an important role in the
regulation of epidermal keratinocytes proliferation, terminal differentiation, cytokine production, and
inflammation [49–51]. AP-1 subunits’ expression levels are downregulated in lesioned compared
with nonlesioned psoriatic skin [52,53]. We determined the effect of fisetin on the expression of AP-1
factors in NHEKs and observed that fisetin increased the nuclear expression of members of AP-1 factor
subunits, including Fos (Fra-1/2, c-Fos, Fos B) and Jun (c-Jun, JunB, JunD), as compared to control
cultures (Figure 2D,E).

investigate the mechanistic role of fisetin in psoriasis-like changes driven by epidermal keratinocytes
hyperproliferation. We observed by MTT analysis that IL-22 treatment of NHEK significantly
induced proliferation (117 ± 0.16%) compared to the control (100 ± 0.11%) (Figure S1, p < 0.01). When
NHEK cultures were treated with 10 and 20 µ M fisetin for 24 h before stimulation with 20 ng/mL of
rhIL-22, IL-22-induced proliferation (117 ± 0.16%) was significantly reduced to 75 ± 0.54%, and 65
±
Cells 2019, 8, 1089
11 of 27
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3.3. Fisetin Regulates IL-22-Induced Keratinocyte Proliferation by Inhibiting the PI3K/AKT and mTOR
Studies
have demonstrated that IL-22-induced proliferation of NHEK is mediated through the
Pathway
Components
PI3K/AKT/mTOR signaling pathway [38,56,60]. Therefore, to mechanistically elucidate how fisetin

It is known that type-17 cytokines such as IL-17 and IL-22 play critical roles in psoriasiform
pathology [54,55], including Akt/mTOR activation [56,57]. In this context, the modulation of
PI3K/Akt/mTOR activity is known to promote epidermal hyperplasia and exert distinct regulatory roles
in the same innate immune cells that are implicated in the immunopathogenesis of psoriasis [31,58,59].
Here, we employed recombinant human (rh) IL-22-activated keratinocytes in vitro to investigate the
mechanistic role of fisetin in psoriasis-like changes driven by epidermal keratinocytes hyperproliferation.
We observed by MTT analysis that IL-22 treatment of NHEK significantly induced proliferation
(117 ± 0.16%) compared to the control (100 ± 0.11%) (Figure S1, p < 0.01). When NHEK cultures were
treated with 10 and 20 µM fisetin for 24 h before stimulation with 20 ng/mL of rhIL-22, IL-22-induced
proliferation (117 ± 0.16%) was significantly reduced to 75 ± 0.54%, and 65 ± 1.09%, respectively
(Figure S1, p < 0.01).
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TNF-α treatment increased the levels of p-p38, p-JNK, PI3K (p110a and p85), p-p90RSK, p-Akt, p-ERK,
(Figure 4). At 30 min, TNF-α treatment increased the levels of p-p38, p-JNK, PI3K (p110a and p85),
and p-S6 (Figure 4). These TNF-α-induced effects were significantly inhibited upon pretreatment with
p-p90RSK, p-Akt, p-ERK, and p-S6 (Figure 4). These TNF-α-induced effects were significantly
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the latter of which was enhanced by fisetin treatment (Figure 4).
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* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.
*** p < 0.001, and **** p < 0.0001.
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(Figure 5). It has been shown that treatment of NHEK with TPA can induce an inflammatory response
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Oftreatment
note, fisetin’s
were highly
similar
uponeffects
TPA stimulation
(Figure
5). to the effects elicited by 1, 25 hydroxyvitamin-D3 (Vit-D3 )
treatment upon TPA stimulation (Figure 5).
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Figure 5. Fisetin
reduces
thethe
inflammatory
response
in 12-O-tetradecanoyl-phorbol-13acetateacetate
(TPA)Figure
Fisetin
reduces
inflammatory
response
in 12-O-tetradecanoyl-phorbol-13activated NHEK.NHEK.
NHEKs
were pretreated
with orwith
without
different
concentrations
of fisetin
and
(TPA)-activated
NHEKs
were pretreated
or without
different
concentrations
of(10
fisetin
20
µ
M)
for
24
h,
before
stimulation
with
or
without
100
ng/mL
of
TPA.
The
release
of
pro(10 and 20 µM) for 24 h, before stimulation with or without 100 ng/mL of TPA. The release of
inflammatory cytokines
(IL-1(IL-1
α, IL-1
IL-6,
TNF-α,
and TGF-α)
in condition
culture
pro-inflammatory
cytokines
α, β,
IL-1
β, IL-8
IL-6,(CXCL8),
IL-8 (CXCL8),
TNF-α,
and TGF-α)
in condition
media was
measured
by Procarta-based
multiplexmultiplex
immunoassay.
Fisetin pretreatment
suppressed
culture
media
was measured
by Procarta-based
immunoassay.
Fisetin pretreatment
TPA-induced
secretion ofsecretion
these proinflammatory
mediators mediators
to values to
similar
that ofto 1,that
25
suppressed
TPA-induced
of these proinflammatory
valuestosimilar
dihydroxyvitamin
D3 (Vitamin
D3) pretreatment.
Values
areare
thethe
mean
three
of
1, 25 dihydroxyvitamin
D3 (Vitamin
D3) pretreatment.
Values
mean± ±SD
SDofofresults
results from three
independent
independent experiments
experiments each
each performed
performed in
inquadruplicate.
quadruplicate. Statistical
Statistical significance
significance was
wasdetermined
determined
using
and
Tukey’s
multiple
comparison
test. test.
Significance
of comparisons
were made
usingone-way
one-wayANOVA
ANOVA
and
Tukey’s
multiple
comparison
Significance
of comparisons
were
for
TPA-stimulated
alone cells
TPA-stimulated
and fisetin/vitamin
D3 -treated
cells, cells,
and also
made
for TPA-stimulated
aloneversus
cells versus
TPA-stimulated
and fisetin/vitamin
D3-treated
and
between
unstimulated
control
cells versus
fisetin/vitamin
D3-treated
cells, cells,
as denoted
by * pby
< 0.05,
also between
unstimulated
control
cells versus
fisetin/vitamin
D3-treated
as denoted
*p<
**0.05,
p < **
0.01,
p <***0.001,
and ****
< 0.0001.
p < ***
0.01,
p < 0.001,
andp****
p < 0.0001.
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effect of
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Altogether,
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and
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Figure 6. Fisetin suppresses the expression and secretion of IFN-γ and IL-17 in activated human
Figure 6. Fisetin suppresses the expression and secretion of IFN-γ and IL-17 in activated human
peripheral blood mononuclear cells (PBMC). PBMC were prepared from the circulating blood from three
peripheral blood mononuclear cells (PBMC). PBMC were prepared from the circulating blood from
different healthy blood donors, and were cultured without (resting) or with anti-CD3 plus anti-CD8
three different healthy blood donors, and were cultured without (resting) or with anti-CD3 plus anti(a-CD3/a-CD28), either treated with 10 µM of fisetin or the vehicle alone (-) for 10 min before activation.
CD8 (a-CD3/a-CD28), either treated with 10 µ M of fisetin or the vehicle alone (-) for 10 min before
(A) PBMC were activated for 6 h before measurement of the type-1 and type-17 proinflammatory
activation. (A) PBMC were activated for 6 h before measurement of the type-1 and type-17
cytokines
IFN-γ (IFNG) and IL-17A (IL17A) mRNA expression levels. Fold change in mRNA levels
proinflammatory cytokines IFN-γ (IFNG) and IL-17A (IL17A) mRNA expression levels. Fold change
compared
resting
cells, whose
expression
level expression
was fixed level
at 1, were
determined.
± SE are
in mRNAtolevels
compared
to resting
cells, whose
was fixed
at 1, wereMeans
determined.
shown,
and
log10
transformation
followed
by
paired
t-test
was
used
to
compare
mRNA
levels
Means ± SE are shown, and log10 transformation followed by paired t-test was used to compare in
a-CD3/a-CD28-activated
PBMC with or without
fisetin.
(B) PBMC
activated
48 h in
mRNA levels in a-CD3/a-CD28-activated
PBMC with
or without
fisetin.were
(B) PBMC
were for
activated
forthe
indicated
conditions
and
secretedand
cytokines
(IFN-γ,
IL-17A,
and IL-17A,
IL-4) present
in the
cell culture
48 h in the
indicated
conditions
secreted
cytokines
(IFN-γ,
and IL-4)
present
in the media
cell
were
measured
ELISA.
Means
SD areMeans
shown± and
theshown
pairedand
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to compare
culture
media by
were
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by±ELISA.
SD are
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paired
was usedvalues
to
between
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and
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(–) and
for a-CD3/a-CD28-activated
PBMC.
compare
values
between
fisetin
no fisetin (–) for a-CD3/a-CD28-activated
PBMC.

3.6.
Topical
Application
Features,Suppresses
SuppressesProliferation,
Proliferation,and
and Modulates
3.6.
Topical
ApplicationofofFisetin
FisetinModulates
Modulates Psoriasis-Like
Psoriasis-Like Features,
Differentiation in a T Cell-Induced Three-Dimensional (3D) Full-Thickness Reconstituted Human Skin Model
Modulates Differentiation in a T Cell-Induced Three-Dimensional (3D) Full-Thickness Reconstituted
of Psoriasis (FTRHSP)
Human Skin Model of Psoriasis (FTRHSP)

Since human psoriatic skin lesion is phenotypically characterized by increases in epidermal
Since human psoriatic skin lesion is phenotypically characterized by increases in epidermal
hyperplasia, antimicrobial peptides, inflammation, and aberrant differentiation and signaling
hyperplasia, antimicrobial peptides, inflammation, and aberrant differentiation and signaling
cascades [36,37,65,66], we determined the effect of fisetin on the established FTRHSP model, which
cascades [36,37,65,66], we determined the effect of fisetin on the established FTRHSP model, which
mimics
in vivo
features
of psoriatic
skin lesions
with Vit-Dwith
five3. days
administering
3. After
mimics
in vivo
features
of psoriatic
skin compared
lesions compared
Vit-D
Afterof five
days of T
cells
to
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and
molecular
administering T cells to the 3D human skin equivalents (day 15 from start), tissues were harvested
as
markers
epidermal
inflammation,
and proliferation
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as indicated
above of
and
moleculardifferentiation,
markers of epidermal
differentiation,
inflammation,
and proliferation
were in
thedetermined
protocol inasFigure
7A. We
observed
that
FTRHSP
(RHSE) that
tissues
generated
by co-culture
indicated
in the
protocol
in control
Figure 7A.
We observed
control
FTRHSP
(RHSE)
with
nonactivated
CD4+
T
cells
showed
more
condensed
epithelium.
In
contrast,
the
regenerated
tissues generated by co-culture with nonactivated CD4+ T cells showed more condensed epithelium.
3DInFTRHSP,
CD4+
T cells, recapitulated
several
features
of humanseveral
psoriatic
contrast, incorporating
the regeneratedactivated
3D FTRHSP,
incorporating
activated CD4+
T cells,
recapitulated
lesion,
withoflesser
cornification
including
in epidermalincluding
thickness,
proliferation,
and other
features
human
psoriatic lesion,
withincreases
lesser cornification
increases
in epidermal
thickness,
proliferation,
and other
changes
in the
aforementioned
features
(Figure 2B,C;
not
changes
in the
aforementioned
features
(Figure
2B,C;
data not shown).
Furthermore,
as data
previously
shown).[36,37],
Furthermore,
as previously
reported
[36,37],
fisetin-treated
FTRSHP tissues
co-cultured
reported
fisetin-treated
FTRSHP
tissues
co-cultured
with activated
CD4+ T
cells had awith
much
thinner viable epidermis, similar to control tissues. These observations were comparable to the effects
elicited by a single dose of Vit-D3 (0.1 µM) (Figure 7B,C).
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observations were comparable to the effects elicited by a single dose of Vit-D3 (0.1 µ M) (Figure 7B,C).
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Fisetin modulated
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toto
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with
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ananadditional
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with
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every
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(B)
Photomicrographs
of
modified
Mayers’s
hematoxylinmedia replenishment every alternate day. (B) Photomicrographs of modified Mayers’s hematoxylinand eosin-stained control RHSE, FTRHSP, and FTRHSP treated with/without fisetin/Vit-D3
and eosin-stained control RHSE, FTRHSP, and FTRHSP treated with/without fisetin/Vit-D3 reconstructs,
reconstructs, scale bar; top panel 20 μM, and bottom panel 50 µ M. (C) Bar graphs showing
scale bar; top panel 20 µM, and bottom panel 50 µM. (C) Bar graphs showing quantification of changes
in the thicknesses of; the viable epidermis (left panel), which significantly decreased in treated group
vs. FTRHSP, and stratum corneum (right panel), which significantly increased in treated group vs.
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quantification of changes in the thicknesses of; the viable epidermis (left panel), which significantly
decreased in treated group vs. FTRHSP, and stratum corneum (right panel), which significantly
FTRHSP. The FTRHSP was generated and treated under different conditions (including with or without
increased in treated group vs. FTRHSP. The FTRHSP was generated and treated under different
testconditions
agents fisetin
or Vit-D
analyzed
detailed
methods
section.
Significant differences between
3 ), and
(including
with
or without
testas
agents
fisetin
or Vit-D
3), and analyzed as detailed methods
means
±
standard
deviation
were
determined
as
denoted
by
*
p
<
0.05,
** pdetermined
< 0.01, andas
***denoted
p < 0.001
section. Significant differences between means ± standard deviation were
byvs.
control
RHSE.
* p < 0.05, ** p < 0.01, and *** p < 0.001 vs. control RHSE.

Additionally, by the analysis of immunostained FTRHSP tissues for the expression of
Additionally, by the analysis of immunostained FTRHSP tissues for the expression of psoriasispsoriasis-related skin protein markers, we observed that, compared with control tissues, the terminal
related skin protein markers, we observed that, compared with control tissues, the terminal
differentiation process was perturbed, as demonstrated by increased expression of Ki67 (proliferation
differentiation process was perturbed, as demonstrated by increased expression of Ki67 (proliferation
(data not shown)) and aberrant increase and expression of differentiation markers (filaggrin, K-10,
(data not shown)) and aberrant increase and expression of differentiation markers (filaggrin, K-10,
involucrin,
TGase-1, and junctional protein desmoglein-1) (Figures 8 and 9, Figure S2). Interestingly,
involucrin, TGase-1, and junctional protein desmoglein-1) (Figures 8, 9, and S2). Interestingly, we
weobserved
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thatthe
thetopical
topicalapplication
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Vit-D
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3 after
3 after
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of
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and desmoglein
in the
spinous via
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including filaggrin,
K-10, involucrin,
TGase-1,1 and
desmoglein
1 granular
in the
epidermal
cell
layers
of
the
FTRHSP
(Figures
8
and
9,
Figure
S2).
spinous via granular epidermal cell layers of the FTRHSP (Figures 8, 9, and S2).
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40 ,6-diamidino-2-phenylindole

mounted in mounting medium containing
(DAPI) and analyzed
Samples were mounted in mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI) and
microscopically. Immunofluorescence staining analysis of differential staining showing the protein
analyzed microscopically. Immunofluorescence staining analysis of differential staining showing the
expressions of early (K10) and late (involucrin) differentiation markers in control RHSE and FTRHSP
protein expressions of early (K10) and late (involucrin) differentiation markers in control RHSE and
under different treatment conditions. Stainings are shown in red and green, respectively, and DAPI
FTRHSP under different treatment conditions. Stainings are shown in red and green, respectively,
in blue and results are representative images of two independent experiments each performed in
and DAPI in blue and results are representative images of two independent experiments each
quadruplicate in comparison to the control and treated FTRHSP. Scale bar = 20 µm.
performed in quadruplicate in comparison to the control and treated FTRHSP. Scale bar = 20 μm.

Figure
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expression
levels
Figure
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in
control
RHSE
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or Vit-D
-treated
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Results
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different
treatment
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or 3Vit-D
3-treated
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areResults
representative
of three independent
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each performed
in quadruplicate
and comparing
are representative
of three independent
experiments
each performed
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control
RHSEcontrol
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treated
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Data
greenData
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(Dsgl-1);
red (filaggrin),
blueand
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is and
merged
representation.
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mixed
is merged representation.
Dsgl-1 = desmoglein-1.
bar = 20 μm.
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compared with control tissues, the activated T cells co-cultured 3D FTRHSP tissues showed increased

compared
with control
tissues, the
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co-cultured
3D FTRHSP
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increased
staining/induction
expression
of activated
psoriasin Tand
(Figure
10A–G),tissues
as well
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staining/induction
expression
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and
p-p70S6K
(Figure
10A–G),
as
well
as
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secretion
secretion of IL-17A (Figure 10H). Topical application of fisetin or Vit-D3 suppressed the observed
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and
IL-17A in the
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3 suppressed
the(Figure
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10).
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(F,G)
For
densitometric
quantification,
each
color
image
was
separated
into
epidermis. (F,G) For densitometric quantification, each color image was separated into its green,
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its
green,
blue,
and
red
channel
components
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ImageJ
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(National
Institutes
of
Health,
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Bethesda,
MD, USA),
and
green and
redused
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were used
analyze mean
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USA),
and green
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were
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Data intensity.
shown here
Data shown here are mean fluorescence intensity ± SEM. (H) Differential protein expression levels of
are mean fluorescence intensity ± SEM. (H) Differential protein expression levels of IL-17A secreted in
IL-17A secreted in the conditioned media of FTRHSP cultures. Pro-inflammatory cytokines IL-17A in
the conditioned media of FTRHSP cultures. Pro-inflammatory cytokines IL-17A in conditioned media,
conditioned media, were analyzed when 3D FTRHSP were treated without and with fisetin (10–30
were analyzed when 3D FTRHSP were treated without and with fisetin (10–30 µM) treatment or 0.1 µM
µ M) treatment or 0.1 µ M Vit-D3 for five days following activation by co-culturing with antiVit-D3 for five days following activation by co-culturing with anti-CD3/CD28 activated CD4+ T cells
for seven days as described in Section 2.12. Significant differences were determined and significance
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of comparisons were made for the expression levels of the target proteins of FTRHSP tissues versus
fisetin or Vitamin D3 -treated FTRHSP, corresponding to the solid lines, and also between nonactivated
T cell-exposed control RHSE versus FTRHSP tissues, indicated by the broken lines, as denoted by
* p < 0.05, ** p < 0.01, and *** p < 0.001.

4. Discussion
In spite of recent progress in the understanding of the underlying molecular basis of psoriasis
pathogenesis, existing treatment strategies still yield fluctuating and often elusive outcomes; hence,
some effective treatments are generally associated with serious side effects. Also, recent efficacious
synthetic agents are unrealistically expensive. Therefore, it is necessary to look into cheaper, safe,
and cost-effective antipsoriatic agents. In this respect, medicinal plants have long been used as
traditional remedies and are still used by over 75% of the world’s population to meet healthcare needs
(World Health Organization, 2013 [67]. Bioactive natural ingredients hold promise and remain a source
of potential new therapeutics, because the identification of their constituent bioactive phytochemicals
allows for the development of novel, clinically useful, cheaper, and relatively safe drugs [68].
In this study, we demonstrated that fisetin has direct prodifferentiative, antiproliferative,
and anti-inflammatory effects on both 2D and 3D cultures of keratinocytes and immune cells. To our
knowledge, this is the first report indicating a direct effect in simplified and complex 3D systems
of psoriasis-like disease. To investigate the effect of fisetin on NHEK differentiation, we selected
differentiation markers relevant to psoriatic skin lesions, reflecting different stages of differentiation.
K1 and K10, “often regarded as early keratinization markers [2],” are among the first proteins expressed
by differentiating keratinocytes, indicative of the fundamental switch from the basal proliferative to
the postmitotic phenotype. This switch is dysregulated in human and murine psoriatic skin lesions,
and psoriatic keratinocytes maintain their proliferative capacity into the suprabasal and granular
layers [4,6,10,30,38,51,69]. We report that fisetin significantly induced protein expression of the early,
intermediate, and late markers of keratinocyte differentiation after 24–48 h of treatment. The biphasic
effect of fisetin on K10 and other early markers, with concentrations greater than 10 µM inducing
less expression levels of K10 and caspase-14, is likely because higher concentrations of fisetin drive
keratinocytes to late differentiation. At later stages of differentiation, a decline in K10 and caspase-14
expression is expected, accompanied by a dose-dependent increase in TGase activity and protein
expression, a late marker of differentiation that facilitates terminal differentiation and formation of the
cornified envelope [48]. Thus, increased expression of K10 and TGase-1 delineates the effect of fisetin not
only to initiate keratinocyte differentiation, but also to complete the barrier integrity stage. Furthermore,
psoriatic lesions exhibit aberrant and reduced distribution and expression of epidermal TGase [70],
and other differentiation markers including caspase-14, filaggrin, and involucrin, etc., resulting
in hyperproliferation and parakeratotic skin [38,71,72]. Cutaneous inflammation in hyperplastic
psoriasis skin lesions is often associated with increased expression of markers of proliferation,
inflammation, and proinflammatory factors. The characteristic hallmarks of psoriasiform disease
include the antimicrobial peptides psoriasin (S100A7) and koebnerisin (S100A15), two epidermal
S100 calcium-binding proteins [66,73,74] with distinct roles but both serving as proinflammatory
alarmins and chemoattractants [75], and cytokines. Moreover, the overexpression of the components of
mTOR/PI3K/Akt and associated signaling has been associated with psoriatic disease [30,31,76]. In this
study, fisetin (1-40 µM) treatment of NHEKs significantly increased TGase enzyme activity by 13–120%,
as well as the protein expressions of TGase-1 and other differentiation markers often observed to be
downregulated in lesioned psoriatic skin [38,44]. Therefore, the antiproliferative and prodifferentiative
effects of fisetin on keratinocytes suggest that fisetin may correct the proliferative and differentiation
imbalances observed in psoriatic keratinocytes.
Importantly, the effect of fisetin was examined on inflammation, another major hallmark of
psoriasis, by analyzing the expression and secretion of key psoriatic cytokines induced by known
activators of human keratinocytes and immune cells. These immune-cell-derived cytokines are capable
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of activating keratinocytes, thereby exacerbating flare-ups [10]. Therefore, the role of inflammatory
and type-17 cytokines in the psoriatic cytokine network has led to the development of antipsoriatic
biologic drugs targeting TNF-α and IL-17A. Examples include etanercept (Enbrel® ), a TNF-α antagonist
and secukinumab, an antibody anti-IL-17A antagonist for psoriasis treatment [77–79]. Furthermore,
high serum levels of TNFα and IL-6 are observed in psoriasis patients compared with healthy
controls [80], and IL-1α, which is primarily produced by skin keratinocytes, regulates proliferation
and differentiation and dictates immune function [81], via priming IL-23-induced modulation of
IL-17A production by T cells [82–85]. Overexpression of IL-1α in basal epidermal layers of transgenic
mouse model leads to a psoriasis-like phenotype with keratinocyte hyperplasia and immune cell
infiltration [86–88]. Here, inflammatory cytokine production in keratinocytes was stimulated by
a known inducer of keratinocyte inflammatory response, TPA [61], while PBMCs were activated
by anti-CD3/anti-CD28 treatment, which mimics antigen presentation to lymphocytes [40]. Since
keratinocytes are the major source of a spectrum of different cytokines including IL-1, IL-6, and TNFα
in skin inflammatory responses [8,10,89], by stimulating NHEKs with TPA, we presumably mimicked
the initiation phase of the psoriatic process [38,90]. Our data on both multiplexed and sandwich ELISAs
showed that fisetin was capable of efficiently inhibiting the production of inflammatory cytokine
induced in keratinocytes, PBMCs, and activated-CD4+ T cells co-cultured with 3D FTRHSP. Among the
cytokines downregulated by fisetin were Th-1/Th-17 cytokines, including IL-17A and IFN-γ. Therefore,
we propose that fisetin, by inhibiting proliferation, inducing differentiation, and downregulating the
psoriatic cytokine network in keratinocytes and immune cells, could restore keratinocyte and skin
homeostasis, and may act as a possible antipsoriatic agent, as suggested by the 3D psoriatic skin
model studies. Furthermore, these findings suggest that fisetin exerts inhibitory functions on the two
major cell types involved in psoriasis pathogenesis, keratinocytes, and immune cells by inhibiting the
activation of PI3K/AKT/mTOR and MAPK pathway components. The induction of ERK1/2 activation
by fisetin is a mechanistic phenomenon observed in several other studies by our team and others.
This is reflected in relation to the activation of cutaneous keratinocyte differentiation (specialized
program cell death in keratinocytes) rather than the expected induction of proliferation [91,92],
and the result is not surprising as constitutive activation of ERK is related to apoptosis. Targeting
immune cells and their mediators is the ultimate approach to treat psoriasis. Moreover, considering
the essential role of keratinocyte crosstalk with immune cells in inflammatory skin diseases like
psoriasis, targeting the inflammatory mediator network from both keratinocytes and immune cells,
as well as the antiproliferative and prodifferentiation potential, may enhance the antipsoriatic effect
of a compound such as fisetin. Considering that fisetin exerts a pleiotropic effect, targeting the
three major hallmarks of psoriasis as a single, natural agent, and is safe and effective, fisetin may
also be less compromising to the patient’s immune system. The observed increased expression of
psoriasin (S100A7), an antimicrobial peptide in the generated CD4+ T cells activated in 3D FTRHSP
compared to normal FTRHSP, was suppressed by topical fisetin treatment to values comparable to the
suppression induced by physiologic Vit-D3 [60,75,93]. We showed earlier the increased expression of
keratinocyte-induced immune mediator secretion without immune-cell-derived cytokines in psoriatic
skin equivalents [37], which are critical facets in the pathogenesis of psoriasis [93]. Herein, we observed
that fisetin inhibited the increased release of both keratinocyte and activated immune-cell-associated
Th1/Th-17 pro-inflammatory cytokines production, including IL-17A, TNF-a, IFN-γ, etc. It is important
to note that the inculcated keratinocytes and activated immune cells in the currently established
FTRHSP model elicit and mimic the feedback loop often induced by specific immune cells in the
immunopathogenesis of psoriatic skin lesions. In view of the intricacy of psoriasis etiology, it is
noteworthy that agents like fisetin that are capable of rescinding numerous critical endpoints in
psoriasiform disease are prospective therapeutic agents for the control of psoriasis.
To the best of our knowledge, this study demonstrates for the first time the direct effects of
fisetin on psoriasis-like features in 2D and 3D psoriasis-like systems, and thus highlights its likely
multifactorial prospect as an agent from natural botanical sources consumed on a daily basis. This could
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pique interest in its development for preventing or slowing the progression of psoriasis and other
inflammatory diseases. Furthermore, granted that the current model is promising, additional studies
employing complementary animal and humanized murine psoriasis-like skin models that integrate
more of the immune axis (e.g., activated dendritic cells) are needed to further corroborate the detailed
mode of action and efficacy of fisetin without involving too much animal experimentation. Taken
together, the current study provides a rationale for future preclinical proof-of-concept studies leading
to clinical studies to evaluate fisetin for the control of psoriasis in human patients.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/8/9/1089/s1,
Figures S1 and S2: Figure S1: Fisetin significantly and dose-dependently suppressed the IL-22 induced proliferation
of 2D culture NHEKs by MTT assay, compared with precancerous (HaCaT) and cancer (A431) cell lines. Figure S2:
Representative photomicrographs of immunofluorescent staining showing the protein expression levels of
differentiation marker (TGase-1) in control (RHSE) and FTRHSP conditions versus (fisetin or vit-D3)-treated
FTRHSP tissues. Data green (TGase-1); blue (DAPI) and mixed staining is merged representation. Results are
representative of three independent experiments each performed in quadruplicate and comparing control RHSE
vs treated FTRHSP. TGase-1 = transglutaminase-1. Scale Bar = 20 µm.
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